Health
Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients – News-Medical.Net
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow. They can occur spontaneously or secondary to treatment for other cancers, so called therapy related disease, which is frequently associated with a mutation of the tumor suppressor gene TP53. Standard treatment for these patients includes hypomethylating agents such as azacitidine or decitabine but unfortunately outcomes are very poor.
Patients with TP53-mutant disease, which is…
-
General18 hours agoMan dies in daylight shooting in Sydney’s north-west
-
Noosa News20 hours agoWhy the Brisbane City Hall clock has fallen silent
-
General19 hours agoMurder trial begins for man accused of killing and burning David Collisson near Mudgee
-
Noosa News19 hours agoGlencore receives taxpayer bailout to save Mt Isa mining jobs